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Purpose: Although carotid endarterectomy (CEA) is recommended as a treatment for carotid 
stenosis rather than carotid artery stenting (CAS), CAS has been preferred in Korea. The aim of 
this study was to analyze long-term outcomes after CAS compared with CEA using Korean na-
tionwide insurance data. 
Materials and Methods: We obtained all data from the nationwide database of the Health 
Insurance Review & Assessment Service (HIRA) during the study period using several codes 
regarding the procedure or operation. We included the HIRA data, which included at least one-
year follow-up after the procedures. The outcomes associated with both procedures were 
death, recurrence of ischemic stroke, and admission for cerebral hemorrhage. 
Results: A total of 16,065 eligible patients who were treated with CAS or CEA between 
1 January 2007 and 31 December 2016 were analyzed. The number of patients with CAS and 
CEA was 12,173 (75.8%) and 3,892 (24.2%), respectively. 8,976 patients (55.9%) were classified 
as symptomatic patients. CAS was associated with a higher risk of all-cause mortality (adjusted 
hazard ratio [HR], 1.282; 95% confidence interval [CI], 1.173–1.400). The adjusted rates for recur-
rent ischemic stroke and cerebral hemorrhage between CAS versus CEA were 24.9% versus 
15.9% (HR, 1.474; 95% CI, 1.325–1.639) and 1.5% versus 0.9% (HR, 2.026; 95% CI, 1.322–3.106), 
respectively. In young symptomatic patients, there was no statistically significant difference in 
all-cause mortality and cardiovascular death between CAS and CEA. 
Conclusion: Our study using Korean nationwide insurance data demonstrated similar results 
to previous studies. Until further evidence of CAS is established through prospective studies, 
CAS should be performed in selected patients according to current guidelines.
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INTRODUCTION
Carotid artery stenosis is known to cause about 15% of isch-
emic stroke.1 Carotid endarterectomy (CEA) is recommend-
ed more often than carotid artery stenting (CAS) for the 
treatment of severe carotid stenosis according to European 
guidelines in 2017.2 CAS is indicated as an alternative to CEA 
for symptomatic patients younger than 70 years.2,3 Also, it is 
recommended that CAS be performed instead of CEA if the 
patient has a high-risk anatomical structure or has comorbid-
ities listed in the guidelines of various countries.4
Unlike in Europe and America, CAS has been preferred in 
Korea, because of its non-invasiveness and the limited num-
ber of hospitals capable of performing CEA. As a result, there 
has been a report that CAS is performed three times more 
frequently than CEA every year in Korea.5 In most studies 
evaluating patient outcomes for those receiving carotid re-
vascularization, there were more patients who received CEA 
than CAS, except for randomized clinical trials.6 There was no 
difference in long-term mortality in the randomized clinical 
trials, but the prognosis of patients with CEA was better in 
the observational study.7
In this study, we investigated the long-term prognosis of 
patients with carotid revascularization in Korea where differ-
ent rates of treatment patterns are present.
MATERIALS AND METHODS
Participants
In Korea, all national citizens are required to enroll in the 
Korean National Health Insurance Service (KNHIS). The data-
set is used as the source of research data came from the 
nationwide claim database of KNHIS. We selected the KNHIS 
database entries between January 1, 2007 and December 
31, 2016, which fulfilled at least one-year follow-up after the 
CAS or CEA. KNHIS uses the Korean Classification of Diseases 
(KCD), which is similar to the International Classification of 
Diseases (ICD), to provide consistent diagnostic codes. The 
data of the KNHIS include codes for procedure or operation, 
and can be classified by specific codes, such as M6602 for 
CAS and O0226, O0227, and O2066 for CEA. Research partic-
ipants were selected by including cases with KCD codes of 
I65.2 and I63 related to carotid artery stenosis, and cerebral 
infarction as claim codes in principal and minor diagnoses. 
Participants were selected using several codes for CAS and 
CEA.
This study was conducted to determine the cerebrovas-
cular events after treatment. The risk factors associated with 
cerebrovascular disease of the individuals were identified by 
using KCD codes according to the proposed algorithms.8,9 
Symptomatic patients were defined as those who had been 
hospitalized with cerebral infarction within 180 days prior to 
carotid revascularization.10 The time of death was obtained 
from the KNHIS database and the cause of death was ob-
tained from Statistics Korea. Among the causes of death, 
cardiovascular disease was identified through I00–I99 codes 
until December 31, 2016. The recurrence of cerebral infarc-
tion was defined as a case of readmission with KCD code 
I63 as the principal diagnosis after at least 28 days of carotid 
revascularization. The occurrence of cerebral hemorrhage 
was defined as the case of readmission with KCD codes I60, 
I61, and I62 as the principal diagnosis.11 The event-free sur-
vival time was defined as the time from the first treatment to 
re-admission of ischemic stroke, cerebral hemorrhage, death, 
or the end of the study, which was December 31, 2017. For 
patients who received more than one treatment during the 
study period, only the first treatment was analyzed in the 
study.
Patients treated for disease other than atherosclerotic ca-
rotid stenosis were excluded (carotid artery dissection, aortic 
dissection, cerebral artery dissection, unruptured cerebral 
aneurysm, and Takayasu arteritis). Patients under 45 years of 
age were excluded to include only those patients treated 
with carotid stenosis due to atherosclerosis. We excluded the 
patients treated in 2007 for a year to select patients who re-
ceived only one treatment during the study period (washout 
period) (Fig. 1).
This study was conducted after obtaining approval from 
the Institutional Review Board at Wonkwang University San-
bon Hospital (IRB No. WMCSB 201711-118).
Statistics
Data were analyzed using SAS, version 9.4 (SAS Inc., Cary, 
NC, USA). In order to examine the difference in demograph-
ic data between patients treated with CAS and CEA, the 
Student’s t-test was used for continuous variables, and chi-
square was used for categorical variables. Kaplan-Meier sur-
vival analysis was performed for the time elapsed from the 
time to treat to death or re-admission. The hazard ratio (HR) 
was calculated using the Cox proportional hazards model. A 
95% confidence interval (CI) and a P-value <0.05 were used 
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for to indicate statistical significance.
RESULTS
A total of 16,065 eligible patients who were treated with CAS 
or CEA were analyzed in the validation data set. The mean 
follow-up period was 62 months (range, 12–120). There were 
12,173 patients (75.8%) who received CAS (CAS group) and 
3,892 patients (24.2%) received CEA (CEA group). Eight thou-
sand nine hundred seventy six patients (55.9%) were classi-
fied as symptomatic patients. The proportion of symptomat-
ic patients was higher in patients receiving CAS (60.2%) than 
CEA (42.4%). The mean age was higher in the CAS group 
than CEA group (70.17±8.05 vs. 68.99±7.80). Hypertension, 
diabetes mellitus, dyslipidemia, and ischemic heart disease 
were more prevalent in the CEA group. Atrial fibrillation and 
renal failure showed no significant difference between the 
two groups (Table 1). This difference in demographic data 
was similar when analyzed separately for symptomatic pa-
Table 1. Clinical characteristics of two groups
CAS (n=12,173) CEA (n=3,892) P-value
Male 9,976 (81.95) 3,246 (83.40) 0.0391
Age 70.17±8.05 68.99±7.80 <0.001
Hypertension 7,471 (61.37) 2,674 (68.71) <0.001
Diabetes mellitus 4,724 (38.81) 1,618 (41.57) 0.0021
Dyslipidemia 5,347 (43.93) 1,824 (46.87) 0.0013
Atrial fibrillation 446 (3.66) 169 (4.34) 0.0549
Ischemic heart 
disease
2,934 (24.10) 1,013 (26.03) 0.0152
Renal failure 251 (2.06) 61 (1.57) 0.0516
Symptomatic 7,327 (60.20) 1,649 (42.40) <0.001
Values are presented as mean±standard deviation or number (%).
CAS, carotid artery stenting; CEA, carotid endarterectomy.
Fig. 1. Kaplan-Meier estimates of cumulative incidence of major outcomes. (A) All-cause mortality after treatment. (B) Cardiovascular death after 
treatment. (C) Ischemic stroke for >28 days after treatment. (D) Cerebral hemorrhage for >28 days after treatment. The numbers below the graph are 
the numbers of patients in each group who were event free and still at risk during follow-up period. CAS, carotid artery stenting; CEA, carotid endar-
terectomy.
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tients.
The statistically significant factors associated with all-cause 
mortality were chronic renal failure and old age. CAS was 
also associated with all-cause mortality, but the HR was 1.282 
(95% CI, 1.173–1.400) and lower than other factors (Table 2). 
Patients treated with CAS had an overall higher risk for car-
diovascular death (HR, 1.569; 95% CI, 1.338–1.841) or ischemic 
stroke (HR, 1.474; 95% CI, 1.325–1.639). However, other factors 
were more significantly related to the cardiovascular death or 
ischemic stroke. The risk factors for cardiovascular death were 
old age, chronic renal failure, atrial fibrillation, symptomatic 
case, and CAS. The risk factors for readmission of ischemic 
stroke were symptomatic case, CAS, old age, and atrial fibril-
lation (Table 3). Patients treated with CAS had also higher 
risk for cerebral hemorrhage (HR, 2.026; 95% CI, 1.322–3.106), 
but atrial fibrillation (HR, 2.505; 95% CI, 1.495–4.198) and renal 
failure (HR, 2.771; 95% CI, 1.357–5.656) were more significantly 
related to the cerebral hemorrhage.
Table 2. Multivariate Cox regression analysis of overall HR related to the all-cause mortality
Variable Dead Alive HR (95% CI) P-value
Treatment <0.0001
CAS 2,607 (21.4) 9,566 (78.6) 1.282 (1.173–1.400)
CEA 633 (16.3) 3,259 (83.7) 1
Gender <0.0001
Male 2,755 (20.8) 10,467 (79.2) 1.351 (1.226–1.488)
Female 485 (17.1) 2,358 (81.9) 1
Age <0.0001
≥80 years 582 (35.5) 1,056 (64.5) 2.590 (2.362–2.839)
<80 years 2,658 (18.4) 11,769 (81.6) 1
Hypertension 0.0435
Yes 1,997 (19.7) 8,148 (80.3) 0.928 (0.864–0.998)
No 1,243 (21.0) 4,677 (79.0)
Diabetes mellitus 0.0286
Yes 1,295 (20.4) 5,047 (79.6) 1.082 (1.008–1.162)
No 1,945 (20.0) 7,778 (80.0) 1
Dyslipidemia <0.0001
Yes 1,129 (15.7) 6,042 (84.3) 0.739 (0.687–0.794)
No 2,111 (23.7) 6,783 (76.3) 1
Atrial fibrillation <0.0001
Yes 167 (27.2) 448 (72.8%) 1.465 (1.251–1.716)
No 3,073 (19.9) 12,377 (80.1) 1
Ischemic heart disease 0.2774
Yes 798 (20.2) 3,149 (79.8)
No 2,442 (20.2) 9,676 (79.8)
Chronic renal failure <0.0001
Yes 122 (39.1) 190 (60.9) 2.598 (2.139–3.156)
No 3,118 (19.8) 12,635 (80.2) 1
Symptomatic <0.0001
Yes 2,157 (24.0) 6,819 (76.0) 1.530 (1.421–1.647)
No 1,083 (15.3) 6,006 (84.7) 1
Values are presented as number (%) unless otherwise indiceated.
HR, hazard ratio; CI, confidence interval; CAS, carotid artery stenting; CEA, carotid endarterectomy.
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During the follow-up period, 2,607 patients in the CAS 
group (21.4%) and 633 patients in the CEA group (16.3%) 
died, corresponding to a cumulative incidence of 37.3% (95% 
CI, 35.6–39.0) in the CAS group compared with 29.0% (95% 
CI, 26.3–31.7) in the CEA group. After the perioperative phase, 
2,124 patients treated with CAS (17.4%) and 412 patients 
(10.6%) treated with CEA were admitted due to ischemic 
stroke, corresponding to a cumulative incidence of 24.9% 
(95% CI, 23.6–26.2) in the CAS group compared with 15.9% 
(95% CI, 14.0–17.9) in the CEA group. And, 162 patients treat-
ed with CAS (1.3%) and 26 (0.7%) patients with CEA were ad-
mitted due to cerebral hemorrhage corresponding to a cu-
mulative incidence of 1.5% (95% CI, 1.4–2.0) in the CAS group 
compared with 0.9% (95% CI, 0.6–1.4) in the CEA group (Table 4). 
The incidence of major events during follow-up period was 
significantly lower in the CEA group than CAS group (Fig. 1).
The risk of cerebrovascular events was analyzed by com-
paring the age, symptomatic, and asymptomatic group. 
Table 3. Multivariate Cox regression analysis of the overall HR related to the events
Variable
Ischemic stroke Cardiovascular death
HR (95% CI) P-value HR (95% CI) P-value
Treatment <0.0001 <0.0001
CAS 1.474 (1.325–1.639) 1.569 (1.338–1.841)
CEA 1 1
Gender 0.4382 0.0792
Male
Female
Age <0.0001 <0.0001
≥80 years 1.410 (1.255–1.585) 2.616 (2.266–3.021)
<80 years 1 1
Hypertension 0.8323 0.7568
Yes
No
Diabetes mellitus 0.7391 0.0139
Yes 0.860 (0.763–0.970)
No 1
Dyslipidemia <0.0001 <0.0001
Yes 0.806 (0.744–0.873) 0.699 (0.619–0.789)
No 1 1
Atrial fibrillation 0.0111 <0.0001
Yes 1.272 (1.056–1.532) 1.852 (1.469–2.333)
No 1 1
Ischemic heart disease <0.0001 0.0558
Yes 0.794 (0.719–0.877)
No 1
Chronic renal failure 0.987 <0.0001
Yes 2.603 (1.930–3.510)
No 1
Symptomatic <0.0001 <0.0001
Yes 3.538 (3.207–3.904) 2.120 (1.860–2.417)
No 1 1
HR, hazard ratio; CI, confidence interval; CAS, carotid artery stenting; CEA, carotid endarterectomy.
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There was no statistically significant difference in the risk of 
death between CAS and CEA in patients with symptoms 
less than 70 years old and those older than 80 years. There 
was no statistical difference in the risk of death between CAS 
and CEA in asymptomatic patients between 70 and 80 years 
of age (Fig. 2). The subgroups without significant difference 
in cardiovascular death between CAS and CEA were either 
patients less than 70 years old regardless of symptoms, or 
asymptomatic patients older than 80 years (Fig. 3).
Table 4. Cumulative incidence at about 9 years and hazards for stroke and death in patients treated with CAS compared with CEA
Outcome
CAS (n=12,173) CEA (n=3,892) HR (95% CI) of CAS relative to CEA
N
Cum Inc (%)  
(95% CI)
N
Cum Inc (%)  
(95% CI)
Unadjusted
Adjusted for 
confounders
Ischemic stroke from day 28 2,141 24.9 (23.6–26.2) 412 15.9 (14.0–17.9) 1.82 (1.639–2.020) 1.474 (1.325–1.639)
Cerebral hemorrhage from day 28 162 1.5 (1.4–2.0) 26 0.9 (0.6–1.4) 2.210 (1.460–3.344) 2.026 (1.322–3.106)
Cardiovascular death 1,006 12.2 (11.3–13.1) 184 7.3 (6.1–8.6) 1.836 (1.570–2.148) 1.569 (1.338–1.841)
Death 2,607 37.3 (35.6–39.0) 633 29.0 (26.3–31.7) 1.434 (1.315–1.565) 1.282 (1.173–1.400)
CAS, carotid artery stenting; CEA, carotid endarterectomy; HR, hazard ratio; CI, confidence interval; Cum Inc, cumulative incidence.
Fig. 2. Adjusted hazard ratio for all-cause mortality in patients treated with CAS (relative to patients treated with CEA). CEA, carotid endarterectomy; 
CI, confidence interval; CAS, carotid artery stenting.
Subgroup Age (years) No. of patients CEA Hazard ratio 95% CI P-value
Overall All 16,065 (100%) 3,892 1.282 (1.173-1.400) <0.0001 
<70 7,240 (45.1%) 1,920 1.393 (1.183-1.641) <0.0001 
70 to <80 7,187 (44.7%) 1,677 1.277 (1.138-1.432) <0.0001 
≥80 1,638 (10.2%) 295 1.515 (1.201-1.911) 0.0005 
Symptomatic All 8,976 (55.9%) 1,649 1.260 (1.122-1.416) 0.0001 
<70 3,906 (24.3%) 779 1.228 (0.990-1.523) 0.0618 
70 to <80 4,062 (25.3%) 742 1.231 (1.051-1.441) 0.0099 
≥80 1,008 (6.3%) 128 1.297 (0.963-1.746) 0.0872 
Asymptomatic All 7,089 (44.1%) 2,243 1.317 (1.159-1.508) <0.0001 
<70 3,334 (20.8%) 1,141 1.412 (1.089-1.830) 0.0091 
70 to <80 3,125 (19.5%) 935 1.156 (0.972-1.376) 0.1014 
≥80 630 (3.9%) 167 1.568 (1.071-2.296) 0.0206 
Fig. 3. Adjusted hazard ratio for cardiovascular death in patients treated with CAS (relative to patients treated with CEA). CEA, carotid endarterecto-
my; CI, confidence interval; CAS, carotid artery stenting.
Subgroup Age (years) No. of patients CEA Hazard ratio 95% CI P-value
Overall All 16,065 (100%) 3,892 1.569 (1.338-1.841) <0.0001 
<70 7,240 (45.1%) 1,920 1.543 (1.147-2.074) 0.0041 
70 to <80 7,187 (44.7%) 1,677 1.729 (1.402-2.132) <0.0001 
≥80 1,638 (10.2%) 295 2.232 (1.452-3.433) 0.0003 
Symptomatic All 8,976 (55.9%) 1,649 1.519 (1.247-1.851) <0.0001 
<70 3,906 (24.3%) 779 1.174 (0.852-1.673) 0.3729 
70 to <80 4,062 (25.3%) 742 1.537 (1.175-2.012) 0.0017 
≥80 1,008 (6.3%) 128 2.006 (1.204-3.544) 0.0084 
Asymptomatic All 7,089 (44.1%) 2,243 1.649 (1.257-2.164) 0.0003 
<70 3,334 (20.8%) 1,141 1.712 (0.975-3.006) 0.0614 
70 to <80 3,125 (19.5%) 935 1.530 (1.083-2.162) 0.0158 
≥80 630 (3.9%) 167 1.673 (0.817-3.424) 0.159
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DISCUSSION
The prognosis of patients who received carotid revascular-
ization in this study differed between CAS and CEA groups. 
These results are similar to those of previous studies and 
meta-analysis.6,12 Because of the lack of evidence, current 
guidelines recommend CAS as an alternative to CEA in lim-
ited patients.3,13 CAS is indicated as an alternative to CEA for 
symptomatic patients with high risk comorbidities or anat-
omy. Age is also a factor to be considered in determining 
treatment options. In a previous study, the high risk group of 
CEA was defined as those individuals with severe comorbid-
ities, technical factors, and old age (>80 years).14 Guidelines 
in America and Europe recommend CAS in symptomatic 
patients less than 70 years of age, because periprocedural 
complications and long-term ipsilateral stroke recurrence are 
not different between CAS and CEA.15,16
In this study, mean age and proportion of symptomatic 
patients and males was not different from those of previous 
studies.17,18 The incidence of hypertension, dyslipidemia, 
ischemic heart disease, and renal failure in this study was 
lower than previous studies, but diabetes mellitus was high-
er.7,17,19 Patients who received CAS were less likely to have 
chronic comorbidities unlike a previous study.7 Unlike CEA, 
which is mainly performed in tertiary hospitals, CAS is more 
widely performed in Korean non-tertiary hospitals than in 
Korean tertiary hospitals. Therefore, it is possible that CAS 
can be performed more than CEA, and that there are fewer 
comorbidities in the CAS group due to the characteristics 
of non-tertiary hospitals with relatively less severe patients. 
The factors related to long-term mortality were age, diabetes 
mellitus, renal insufficiency, symptomatic status, and statin 
use in previous studies.20 Similar to a previous study, old age 
(>80 years), symptomatic status, and renal failure were the 
most significant risk factors associated with long-term all-
cause mortality and cardiovascular death in this study.
Long-term all-cause mortality was not different signifi-
cantly between CAS and CEA in the meta-analysis of a ran-
domized controlled study and nationwide cohort study.6,17 
However, there was difference in the all-cause mortality 
between the groups in this study like a prior multi-center 
cohort study.7 The long-term risk of ischemic stroke after ca-
rotid revascularization was higher in the CAS group than CEA 
group in this study, and the HR was similar to the result of a 
meta-analysis and nationwide cohort study.6 The incidence 
of ischemic stroke after carotid revascularization in this study 
was higher than those of previous studies, but the long-term 
mortality was similar. The incidence of cerebral hemorrhage 
after carotid stenting was reported about 0.85–4.4% from 
previous population-based studies and it was 2–6 fold high-
er among CAS relative to CEA.21,22 Although this study was 
based on long-term follow-up, the incidence of cerebral 
hemorrhage and the risk of CAS were similar to those of the 
previous studies. In this study, information regarding death 
is highly reliable, but data regarding the other outcomes are 
not. Even if no neurological symptoms have occurred, there 
may be some patients who were admitted with the ischemic 
stroke code to perform brain magnetic resonance imaging. 
It is possible that the incidence of ischemic stroke has been 
overestimated. 
Long-term outcomes were studied in the sub-group analy-
sis according to the presence of symptom and age. All-cause 
mortality and cardiovascular death were not significantly 
different between CAS and CEA in young and symptomatic 
patients. This result is consistent with current guidelines.2,3 
Also, all-cause mortality was not different between CAS and 
CEA in older symptomatic patients, and cardiovascular death 
was not different in older asymptomatic patients. These re-
sults may support CAS as an alternative measure in elderly 
patients at high risk of CEA.
The limitation of this study lies in the analysis of the claim 
database. There is possibility that incidence of comorbidities 
in this study is lower than in real-world data. The proportion 
of symptomatic patients is similar to previous studies, but 
it may be underestimated also due to lack of clinical infor-
mation. Because admission by specific code was limited to 
occurrence of ischemic stroke or cerebral hemorrhage, it is 
possible that the frequency of cerebrovascular events were 
overestimated. There was no information about re-stenosis. 
In Korea, CAS is sometimes preferred rather than CEA with-
out medical evidence, and there was no clinical information 
about anatomical risk factors related to treatment modality 
choice.
The strengths of our study include the nationwide, large 
real-world data, including high-confidence mortality data. 
Unlike previous studies, this study analyzed many patients 
who underwent CAS rather than CEA. CAS generally did 
not show better results than CEA, but a similar prognosis 
was found in some of the patients using the recommended 
guidelines.
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CONCLUSION
In this nationwide data, the all-cause mortality rate was 
higher in patients with CAS over the long term. However, the 
long-term prognosis of CAS and CEA was similar in young 
symptomatic patients. In the future, a prospective study 
should be performed to select appropriate treatment for 
each patient. Until further evidence of CAS is established 
through prospective studies, CAS should be performed in 
selected patients according to current guidelines.
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